Characteristics, n (%) | HCQ | Steroid | Vit D | Total n (%) |
---|---|---|---|---|
Target sample size info provided | 187 | 106 | 57 | 350 |
Small (≤ 100) | 83 (44.4) | 48 (45.3) | 24 (42.1) | 155 (44.3) |
Medium (101 to 300) | 54 (28.9) | 33 (31.1) | 18 (31.6) | 105 (30) |
Large (> 300) | 50 (26.7) | 25 (23.6) | 15 (26.3) | 90 (25.7) |
Blinding info provided | 170 | 108 | 19 | 297 |
Blinding | 82 (48.2) | 40 (37.) | 16 (84.2) | 138 (46.5) |
Blinding description info provided | 79 | 40 | 16 | 135 |
Single | 14 (17.7) | 11 (27.5) | 2 (12.5) | 27 (20) |
Double | 32 (40.5) | 19 (47.5) | 8 (50) | 59 (43.7) |
Triple/Quadruple | 33 (41.8) | 10 (25) | 6 (37.5) | 49 (36.3) |
Allocation concealment info provided | 12 | 12 | 11 | 35 |
Allocation concealment | 12 (100) | 10 (83.3) | 11 (100) | 33 (94.3) |
Ethics info provided | 76 | 58 | 23 | 157 |
Ethics approval | 75 (98.7) | 58 (100) | 23 (100) | 156 (99.4) |
Trial status info provided | 192 | 108 | 57 | 357 |
Not stated/Unknown | 18 (9.4) | 6 (5.6) | 4 (7) | 28 (7.8) |
Ongoing | 70 (36.5) | 59 (54.6) | 30 (52.6) | 159 (44.5) |
Completed | 34 (17.7) | 20 (18.5) | 18 (31.6) | 72 (20.2) |
Withdrawn/Terminated | 70 (36.4) | 23 (21.3) | 5 (8.8) | 98 (27.5) |